Specificity and Affinity of 26 Monoclonal Antibodies against the CA 125 Antigen: First Report from the ISOBM TD-1 Workshop

K. Nustad; R.C. Bast, Jr.; T.J. O&rsquo;Brien; O. Nilsson; P. Seguin; M.R. Suresh; T. Saga; S. Nozawa; O.P. B&oslash;rmer; H.W.A. de Bruijn; M. Nap; A. Vitali; M. Gadnell; J. Clark; K. Shigemasa; B. Karlsson; F.T. Kreutz; D. Jette; H. Sakahara; K. Endo; E. Paus; D. Warren; S. Hammarstr&ouml;m; P. Kenemans&deg;; J. Hilgers&deg;

doi:10.1159/000217982

Development of new immunoradiometric assay for CA 125 antigen using two monoclonal antibodies produced by immunizing lung cancer cells

Annals of Nuclear Medicine ◽

10.1007/bf03164948 ◽

1988 ◽

Vol 2 (2) ◽

pp. 73-79 ◽

Cited By ~ 7

Author(s):

Mihoko Kunimatsu ◽

Keigo Endo ◽

Tetsuo Nakashima ◽

Toshikazu Awaji ◽

Tsuneo Saga ◽

...

Keyword(s):

Lung Cancer ◽

Monoclonal Antibodies ◽

Cancer Cells ◽

Lung Cancer Cells ◽

Ca 125 ◽

Immunoradiometric Assay ◽

Ca 125 Antigen

Download Full-text

Characterization of CA 125 antigen identified by monoclonal antibodies that recognize different epitopes

Clinical Biochemistry ◽

10.1016/0009-9120(93)90116-n ◽

1993 ◽

Vol 26 (5) ◽

pp. 391-397 ◽

Cited By ~ 4

Author(s):

Hiroshi Kobayashi ◽

Hidekazu Ohi ◽

Nobuhiko Moniwa ◽

Hiromitsu Shinohara ◽

Toshihiko Terao

Keyword(s):

Monoclonal Antibodies ◽

Ca 125 ◽

Ca 125 Antigen

Download Full-text

5059680 Method of isolating CA 125 antigen

Biotechnology Advances ◽

10.1016/0734-9750(92)91393-s ◽

1992 ◽

Vol 10 (1) ◽

pp. 127

Keyword(s):

Ca 125 ◽

Ca 125 Antigen

Download Full-text

Comparison of seven immunoassays for the quantification of CA 125 antigen in serum

Clinical Chemistry ◽

10.1093/clinchem/44.7.1417 ◽

1998 ◽

Vol 44 (7) ◽

pp. 1417-1422 ◽

Cited By ~ 29

Author(s):

Elvira M Davelaar ◽

Gerard J van Kamp ◽

Rob A Verstraeten ◽

Peter Kenemans

Keyword(s):

Ovarian Cancer ◽

Clinical Performance ◽

Correlation Coefficients ◽

Roc Curves ◽

Ca 125 ◽

Serum Samples ◽

Pelvic Tumors ◽

Value Range ◽

Patient Groups ◽

Ca 125 Antigen

Abstract Seven CA 125 immunoassays were compared for their clinical performance. CA 125 concentrations were determined in 289 serum samples obtained from women with benign pelvic tumors (samples from 98 patients) and patients with various cancers (samples from 111 patients). In the range of 0–1000 kilounits/L, all assays tested were linearly correlated, with correlation coefficients ranging from 0.89 to 0.99. In relation to the original Centocor CA 125 assay, there was an overall tendency to measure higher absolute values in the lower CA 125 value range. This was not seen in relation to the Centocor CA 125 II assay. ROC curves (benign vs pretreatment ovarian cancer patients) were nearly identical for all assays, and the areas under the ROC curves were not markedly different. We conclude that the CA 125 assays tested are strongly related to each other and are clinically reliable for the quantification of serum CA 125 and that none of the assays offers higher diagnostic accuracy or better discrimination between patient groups, especially not in the lower ranges.

Download Full-text

Clinical Evaluation of a New Two-Site Assay for CA125 Antigen

The International Journal of Biological Markers ◽

10.1177/172460089100600208 ◽

1991 ◽

Vol 6 (2) ◽

pp. 129-135 ◽

Cited By ~ 13

Author(s):

V. Capstick ◽

G.D. Maclean ◽

M.R. Suresh ◽

D. Bodnar ◽

S. Lloyd ◽

...

Keyword(s):

Clinical Evaluation ◽

Response To Therapy ◽

Ca 125 ◽

Unknown Primary ◽

Ovarian Adenocarcinoma ◽

Healthy Donors ◽

Response To Chemotherapy ◽

The Mean ◽

Ca 125 Antigen

As appropriate surgery and chemotherapy can improve both quality of life and survival of patients with ovarian adenocarcinoma, there has been a pressing need for “serodiagnostic” assays to enable close patient monitoring. CA 125 antigen has previously been described as a useful tumor marker of ovarian cancer. This is the first clinical evaluation of a radioimmunoassay using two new monoclonal antibodies, B27.1 and B43.13, that react with separate sites on the glycoprotein marker CA 125. Using the new assay, the majority of patients with clinically or radiologically detectable disease had serum CA 125 antigen levels well above the upper limit seen with random apparently healthy donors, while only three patients who were believed free of disease had elevated levels. Disease progression was associated with increasing values of serum CA 125 antigen, while response to therapy was associated with a steady decline in serum CA 125 antigen levels. Seven patients had steadily rising serum CA 125 antigen levels after initially having normal levels. The mean lead time between rise above normal and clinical or radiological evidence of relapse was 5 months (range 2 to 12 months). The merits of further surgical intervention are illustrated by the serial values of two patients followed after chemotherapy. The assay appears to have value in monitoring response to therapy and in detecting disease relapse at a time when appropriate therapeutic intervention is still possible or likely to be beneficial. Furthermore, monitoring CA 125 antigen was shown to be of benefit in assessing response to chemotherapy in a few patients with metastatic adenocarcinoma of unknown primary, and may be useful in this group of patients in determining those likely to benefit from aggressive chemotherapy.

Download Full-text

Generation of Recombinant Rotavirus with an Antigenic Mosaic of Cross-Reactive Neutralization Epitopes on VP4

Journal of Virology ◽

10.1128/jvi.00601-08 ◽

2008 ◽

Vol 82 (13) ◽

pp. 6753-6757 ◽

Cited By ~ 28

Author(s):

Satoshi Komoto ◽

Masanori Kugita ◽

Jun Sasaki ◽

Koki Taniguchi

Keyword(s):

Amino Acids ◽

Monoclonal Antibodies ◽

Amino Acid ◽

Reverse Genetics ◽

Amino Acid Substitutions ◽

Neutralization Epitope ◽

First Report ◽

P Type

ABSTRACT Recombinant rotavirus (RV) with cDNA-derived chimeric VP4 was generated using recently developed reverse genetics for RV. The rescued virus, KU//rVP4(SA11)-II(DS-1), contains SA11 (simian RV strain, G3P[2])-based VP4, in which a cross-reactive neutralization epitope (amino acids 381 to 401) on VP5* is replaced by the corresponding sequence of a different P-type DS-1 (human RV strain, G2P[4]). Serological analyses with a panel of anti-VP4- and -VP7-neutralizing monoclonal antibodies revealed that the rescued virus carries a novel antigenic mosaic of cross-reactive neutralization epitopes on its VP4 surface. This is the first report of the generation of a recombinant RV with artificial amino acid substitutions.

Download Full-text

Generation of Human Monoclonal Anti-idiotypic Antibodies with Specificity to the Murine Monoclonal Anti-CA 125 Antibody B43.13

The International Journal of Biological Markers ◽

10.1177/172460089601100406 ◽

1996 ◽

Vol 11 (4) ◽

pp. 211-215

Author(s):

J.B. Oltrogge ◽

B. Donnerstag ◽

R.P. Baum ◽

A.A. Noujaim ◽

L. Träger

Keyword(s):

Ovarian Cancer ◽

Monoclonal Antibody ◽

Monoclonal Antibodies ◽

Peripheral Blood Lymphocytes ◽

Cross Reactivity ◽

Tumor Burden ◽

Ca 125 ◽

Enzyme Linked Immunosorbent Assay ◽

Human Monoclonal Antibodies ◽

Ebv Transformation

Two human monoclonal antibodies, HID-7E7 and ROB-6F2, were produced by EBV transformation of peripheral blood lymphocytes (PBL). PBL were obtained from a patient with ovarian cancer who had been exposed several times to a Tc-99m labeled murine monoclonal anti-CA 125 antibody (B43.13, Biomira, Edmonton) for immunoscintigraphy. The HID-7E7 and ROB-6F2 producing B-cells were cloned with a limiting dilution technique and have shown stable immunoglobulin secretion within a period of three years. The human monoclonal antibodies HID-7E7 and ROB-6F2 are of the IgG isotype, and bind with significant affinity to the murine monoclonal antibody B43.13, which was used for immunoscintigraphy. Binding affinity of ROB-6F2 to other murine antibodies could not be detected. Cross reactivity of HID-7E7 to a murine anti-CEA monoclonal antibody was observed. In order to verify the anti-idiotypic character of the generated human antibodies, the ability of HID-7E7 and ROB-6F2, respectively, to inhibit the formation of the CA125/B43.13 complex is demonstrated via an enzyme-linked immunosorbent assay. These human anti-idiotypic antibodies are possible candidates for immunotherapy of ovarian cancer in patients with a small tumor burden following surgery and/or chemotherapy.

Download Full-text